Table 3.
Gene | SNP | Chr | Position (Mb) |
MAF (affected women) |
MAF (controls) |
Minor allele |
Set 1 P | Set 2 P | Set 3 P | Set 4 P | Overall joint P | OR | 95% CI |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NMNAT2 | rs2022013 | 1q25.3 | 181.620476 | 0.3797 | 0.4197 | G | 0.27761 | 0.00061 | 0.04818 | 0.00002 | 1.08E-07 | 0.85 | 0.79–0.9 |
- | rs2431697 | 5q33.3 | 159.812556 | 0.3848 | 0.4342 | C | 0.00180 | 0.05430 | 0.00093 | 0.01260 | 1.00E-10 | 0.82 | 0.77–0.87 |
- | rs6568431 | 6q21 | 106.695499 | 0.4237 | 0.3812 | A | 0.00066 | 0.01535 | 0.00797 | 0.26498 | 1.74E-08 | 1.19 | 1.12–1.27 |
ATG5 | rs573775 | 6q21 | 106.871559 | 0.3178 | 0.281 | T | 0.03760 | 0.00005 | 0.00427 | 0.95153 | 1.36E-07 | 1.19 | 1.12–1.27 |
ICA1 | rs10156091 | 7p21.3 | 8.153619 | 0.1198 | 0.0969 | A | 0.03768 | 0.00003 | 0.03378 | 0.10622 | 1.90E-07 | 1.32 | 1.19–1.47 |
TNPO3 | rs10239340 | 7q32.1 | 128.455746 | 0.324 | 0.3842 | T | 0.04340 | 3.73E-07 | 7.42E-06 | 0.10424 | 6.98E-16 | 0.77 | 0.73–0.82 |
- | rs6601327 | 8p23.1 | 9.432942 | 0.4039 | 0.3649 | C | 0.00059 | 0.06181 | 0.38560 | 0.01097 | 1.99E-07 | 1.18 | 1.11–1.25 |
XKR6 | rs6985109 | 8p23.1 | 10.798995 | 0.5138 | 0.462 | G | 0.00123 | 0.09025 | 0.00082 | 0.00430 | 2.51E-11 | 1.23 | 1.16–1.3 |
XKR6 | rs4240671 | 8p23.1 | 10.805158 | 0.4499 | 0.4947 | A | 0.34769 | 0.12244 | 0.00552 | 0.00347 | 6.60E-09 | 0.75 | 0.68–0.83 |
XKR6 | rs11783247 | 8p23.1 | 10.826285 | 0.5099 | 0.4627 | C | 0.00469 | 0.10787 | 0.00150 | 0.02095 | 8.00E-10 | 1.21 | 1.14–1.28 |
XKR6 | rs6984496 | 8p23.1 | 10.833503 | 0.5078 | 0.4588 | C | 0.00164 | 0.13155 | 0.00066 | 0.02292 | 2.00E-10 | 1.22 | 1.14–1.29 |
C8orf12 | rs7836059 | 8p23.1 | 11.309574 | 0.439 | 0.4871 | T | 0.00606 | 0.08327 | 0.01088 | 0.00647 | 4.00E-10 | 0.82 | 0.78–0.88 |
BLK | rs2248932 | 8p23.1 | 11.429059 | 0.3928 | 0.3475 | T | 0.00751 | 0.45841 | 0.06147 | 0.00001 | 7.00E-10 | 1.22 | 1.14–1.3 |
- | rs10903340 | 8p21.1 | 11.487996 | 0.4593 | 0.4193 | C | 0.00346 | 0.31025 | 0.07304 | 0.02869 | 1.46E-07 | 1.18 | 1.11–1.25 |
LYN | rs7829816 | 8q12 | 57.011940 | 0.1844 | 0.2159 | C | 0.52653 | 0.00187 | 0.00016 | 0.95150 | 5.40E-09 | 0.77 | 0.70–0.84 |
LYN | rs2667978 | 8q12 | 57.060505 | 0.19 | 0.2244 | C | 0.00021 | 0.02071 | 0.00701 | 0.51240 | 5.10E-08 | 0.81 | 0.76–0.88 |
UBE2L3 | rs5754217 | 22q11.21 | 20.269675 | 0.2287 | 0.1953 | A | 0.01589 | 0.00187 | 0.20201 | 0.01842 | 7.53E-08 | 1.22 | 1.14–1.32 |
SCUBE1 | rs2071725 | 22q13.2 | 41.939704 | 0.1176 | 0.1453 | A | 0.00255 | 0.01762 | 0.00015 | 0.84821 | 1.21E-07 | 0.78 | 0.72–0.86 |
Listed are SNPs that exceed P < 2 × 10−7 in the overall joint analysis but not P < 0.05 in each individual set, in contrast to Table 1. The additive model is presented unless the test for lack of fit to an additive model was significant (P < 0.05), as for rs7829816 and rs1015609 (dominant). Chr, chromosome; MAF, minor allele frequency. Odds ratio (OR) is shown with 95% confidence interval (CI) boundaries. Positions are from build 35 throughout.